Cas9 protein, type ii crispr / cas9 gene editing system and use
By screening out novel Cas9 proteins that can recognize multiple PAM sequences, such as HqCas9, DspCas9 and DsuCas9, the existing CRISPR/Cas9 system PAM recognition requirements have been solved, and a wider range of gene editing targeting has been achieved, which has promoted genes. Clinical application of editing technology.
Patent Information
- Application Number
- PCT/CN2023/101584
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2023-06-21
- Publication Date
- 2024-11-14
AI Technical Summary
The existing type II CRISPR/Cas9 gene editing system, especially SpCas9 derived from Streptococcus pyogenes, has strict PAM recognition requirements, which makes certain target sites unavailable, limiting the scope of gene editing.
Three new Cas9 proteins, including HqCas9, DspCas9 and DsuCas9, were screened and developed, which could recognize multiple PAM sequences, such as NGNGNC and NNNAA, expanding the targeting range of gene editing systems.
These novel Cas9 proteins can achieve gene editing in prokaryotic or eukaryotic cells under the guidance of crRNA, significantly increasing the targeting range, overcoming the limitations of SpCas9, expanding the variety of gene editing tools, and promoting gene editing in clinical treatment Application.
Smart Images

Figure CN2023101584_14112024_PF_FP_ABST
Abstract
Description
A Cas9 protein, type II CRISPR / Cas9 gene editing system and applications Technical Field
[0001] The present invention relates to the field of genetic engineering technology, and in particular to a Cas9 protein, a type II CRISPR / Cas9 gene editing system and applications. Background Art
[0002] CRISPR / Cas (Clustered Regularly Interspaced Palindromic Repeats / CRISPR-associated proteins system), a third-generation gene editing tool, boasts simpler design, lower cost, and higher editing efficiency than first-generation ZFNs (Zinc Finger Nucleases) and TALENs (Transcription Activator-like Effector Nucleases), making it the most mainstream gene editing system today. The CRISPR / Cas system is an adaptive immune system that helps bacteria and archaea defend against foreign nucleic acid invasions. It works by storing small fragments of viral genes within their own DNA after being invaded by a virus. Upon a subsequent viral attack, the bacteria can identify the viral genes based on their memory and cut off their DNA, silencing their expression.
[0003] The CRISPR / Cas gene editing system performs its editing function through three steps: acquisition of exogenous DNA, synthesis of crRNA, and targeted interference. The CRISPR array contains direct repeats (DRs) separated by unique spacer sequences within the exogenous DNA. The CRISPR array is transcribed into long transcripts (pre-crRNA, the precursor of CRISPR RNA), which are then processed to produce small, mature CRISPR RNAs (crRNAs) consisting of spacer sequences and portions of adjacent direct repeats. The crRNAs form a complex with the Cas endonuclease and, in some cases, accessory proteins, and serve as a guide for targeting and cleaving foreign nucleic acids, thereby achieving interference. DNA recognition by the Cas–crRNA complex requires the presence of a protospacer adjacent motif (PAM) near the target site, which facilitates self-from-nonself discrimination. CRISPR / Cas gene editing systems are broadly divided into two categories based on the number of different proteases: Class I systems utilize complexes of multiple Cas proteins, such as Cascade, while Class II systems utilize a single effector enzyme, such as Cas9. Currently, the type II CRISPR / Cas gene editing system has become an important tool in gene editing.
[0004] In the existing technology, the Type II system derived from Streptococcus pyogene Cas (SpCas9) has become the most widely used gene editing system due to its high cutting efficiency. This system targets cutting by recognizing a PAM sequence of NGG. However, this PAM requirement also limits the application of SpCas9. Some target sites may not be recognized and edited by SpCas9 due to the presence of fewer GGs. Therefore, based on the shortcomings of the existing Type II CRISPR / Cas9 system, there is an urgent need to develop a new CRISPR / Cas gene editing system.
[0005] Summary of the Invention
[0006] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a Cas9 protein, a type II CRISPR / Cas9 gene editing system and applications.
[0007] To achieve the above object, the technical solution adopted by the present invention is as follows:
[0008] In a first aspect, the present invention screens a Cas9 protein, the amino acid sequence of which is shown in any one of SEQ ID NOs. 1 to 3.
[0009] The present invention screened and obtained three new editing systems whose Cas9 proteins were derived from: an unannotated bacterium, subsequently named HqCas9; DspCas9 from the bacterium Dialister sp.900538805; and DsuCas9 from the bacterium Dialister succinatiphilus. The type II CRISPR / Cas9 gene editing system using the Cas9 protein of the present invention can recognize a variety of different PAM sequences. The PAM sequence recognized by HqCas9 is NGNGNC. The relatively complex PAM can more accurately identify target sites, improving the accuracy of Cas9 protein recognition. The PAMs recognized by DspCas9 and DsuCas9 are similar, with both positions 4 and 5 being A. Both proteins can recognize target sites with the PAM NNNAA. By analyzing the length frequency of "AA" sequence sites on the human genome, it was found that on average, an AA appears every 5bp. This greatly increases the targeting range of DspCas9 and DsuCas9 on the human genome, overcoming the limitations of SpCas9.
[0010] In a second aspect, the present invention provides a nucleotide sequence encoding a Cas9 protein, wherein the nucleotide sequence is shown in any one of SEQ ID NOs. 10 to 12.
[0011] In a third aspect, the present invention provides a type II CRISPR / Cas9 gene editing system, comprising the above-mentioned Cas9 protein, auxiliary protein, CRISPR RNA and tracrRNA sequence.
[0012] The Type II CRISPR / Cas9 gene editing system of the present invention can perform gene editing functions in prokaryotic or eukaryotic cells under the guidance of crRNA. The discovery of the gene editing system of the present invention has expanded the types of gene editing tools and played an important role in promoting the application of gene editing in clinical treatment.
[0013] As a preferred embodiment of the type II CRISPR / Cas9 gene editing system of the present invention, the tracrRNA sequence includes a repeat sequence, and the repeat sequence is shown in any one of SEQ ID NOs. 7 to 9. Furthermore, the tracrRNA sequence is shown in any one of SEQ ID NOs. 14 to 16.
[0014] As a preferred embodiment of the type II CRISPR / Cas9 gene editing system described in the present invention, the nucleotide sequence of the auxiliary protein is shown in any one of SEQ ID NOs. 4 to 6.
[0015] In a fourth aspect, the present invention applies the type II CRISPR / Cas9 gene editing system in gene editing in prokaryotes or eukaryotes.
[0016] In a fifth aspect, the present invention applies the type II CRISPR / Cas9 gene editing system to the preparation of biological gene editing preparations.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] (1) The three type II CRISPR / Cas9 gene editing systems of the present invention can recognize specific PAM sequences (NGNGNC, NNNAA, NNNAA) and can perform gene editing functions in prokaryotic environments or eukaryotic cells under the guidance of crRNA, greatly increasing the targetable range and overcoming the limitations of SpCas9.
[0019] (2) The type II CRISPR / Cas9 gene editing system using the Cas9 protein of the present invention can perform gene editing functions in prokaryotic or eukaryotic cells under the guidance of crRNA. The discovery of the Cas9 protein and gene editing system of the present invention has expanded the types of gene editing tools and played an important role in promoting the application of gene editing in clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is a schematic diagram of the evolutionary tree, system composition, and protein bioinformatics analysis results of the CRISPR / Cas9 gene editing system of the present invention.
[0021] Figure 2 is a diagram of the prokaryotic PAM sequences of three CRISPR / Cas9 gene editing systems of the present invention.
[0022] FIG3 is a prokaryotic interference diagram of three CRISPR / Cas9 gene editing systems of the present invention.
[0023] FIG4 is a diagram showing NC confirmation of prokaryotic interference of three CRISPR / Cas9 gene editing systems of the present invention.
[0024] FIG5 is a scaffold structure diagram of three CRISPR / Cas9 gene editing systems of the present invention.
[0025] FIG6 is a diagram illustrating the optimal length of the eukaryotic cell spacer for the three CRISPR / Cas9 gene editing systems of the present invention.
[0026] FIG7 is a graph showing on-target and off-target detection using GUIDE-seq for the three CRISPR / Cas9 gene editing systems described in the present invention. DETAILED DESCRIPTION
[0027] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below with reference to specific embodiments. Those skilled in the art should understand that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The Cas9 endonuclease described in the present invention is a DNA endonuclease. The N in the base sequence described in the present invention represents any one of A, G, C, and T. The Cas9 protein described in the present invention is a multi-domain DNA endonuclease, including a REC domain, a RuvC domain, an HNH domain, and a PI domain. It can recognize a DNA sequence complementary to the sgRNA at the PAM5' end, and cut the DNA chain complementary to the sgRNA through the HNH domain, and the RuvC domain cuts the non-complementary chain DNA. The crRNA described in the present invention guides the Cas protein to recognize invading DNA in a base complementary manner. The 5' end is a spacer sequence that is complementary to the target DNA, and the 3' end is a repeat sequence. The CRISPR / Cas9 gene editing system of the present invention also requires the participation of tracrRNA. TracrRNA is transcribed separately. TracrRNA and pre-crRNA are combined by editing complementary pairing. After RNase III enzymatic treatment, the 5' part of the spacer sequence and the 3' part of the repeat sequence of the pre-crRNA are formed into a mature crRNA, which is combined with tracrRNA to form a tracrRNA-crRNA complex. By adding a four-base tetraloop (such as "GAAA", "TGAA" or "AAAC" sequence) between the downstream of crRNA and the upstream of tracrRNA, tracrRNA and crRNA can be connected to form a scaffold. The cutting function of the Cas9 endonuclease can be further optimized by adjusting the length of tracrRNA and the length of the recognizable spacer sequence.
[0028] Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.
[0029] Example 1: Three novel CRISPR / Cas9 gene editing systems
[0030] Metagenomic bioinformatics was used to analyze, predict, and screen proteins and components associated with the type II CRISPR / Cas9 gene editing system. Metagenomic annotation was performed using CRISPRCas Finder software. The secondary structures of crRNA and tracrRNA were predicted using NUPACK software, functional domains were predicted using HHpred software, and phylogenetic trees were constructed using FastTree software. Three new type II CRISPR / Cas9 gene editing systems were presented, including Cas9 protein, accessory proteins, CRISPR RNA, and tracrRNA, as shown in Figure 1.
[0031] The present invention screened and identified three novel Cas9 proteins from editing systems: HqCas9, an unannotated bacterium subsequently designated as HqCas9; DspCas9 from Dialister sp. 900538805; and DsuCas9 from Dialister succinatiphilus. The HqCas9 protein encodes 1353 amino acids, the sequence of which is shown in SEQ ID NO. 1; the DspCas9 protein encodes 1383 amino acids, the sequence of which is shown in SEQ ID NO. 2; and the DsuCas9 protein encodes 1389 amino acids, the sequence of which is shown in SEQ ID NO. 3. Phylogenetic tree analysis of these three Cas9 proteins compared to 14 other published Type II CRISPR / Cas9 gene editing systems revealed that HqCas9, DspCas9, and DsuCas9 belong to the Type IIA clade. The three Cas9 proteins share high sequence similarity and are most closely related to FrCas9. The phylogenetic tree is shown in Figure 1A.
[0032] The resulting CRISPR / Cas9 gene editing system consists of the following multiple components: the genetically encoded Cas9 nuclease, the auxiliary proteins Cas1, Cas2, Csn2, the CRISPR array, and the trans-activating CRISPR RNA (trans-activating crRNA, tracrRNA). The composition diagram of the three novel CRISPR / Cas9 gene editing systems described in the present invention is shown in Figure 1B, and the Cas9 protein structure diagram is shown in Figure 1C. The auxiliary protein Cas1, whose sequence is shown in SEQ ID NO.4; the auxiliary protein Cas2, whose sequence is shown in SEQ ID NO.5; the auxiliary protein Csn2, whose sequence is shown in SEQ ID NO.6. The three auxiliary proteins are involved in exogenous gene capture and crRNA maturation.
[0033] The CRISPR array consists of direct repeats and spacer sequences, which are arranged in an alternating pattern, with a spacer between the two repeats. The base composition and length of the repeat sequences are relatively conserved within the same bacteria, but can vary slightly between different bacteria. The repeat sequences corresponding to the three novel CRISPR / Cas9 gene editing systems of the present invention are shown in SEQ ID NOs. 7 to 9, respectively.
[0034] The above sequence information is as follows:
[0035] Example 2: Prokaryotic PAM depletion experiment
[0036] This example uses a prokaryotic PAM depletion experiment to identify the PAM sequence required for the Cas nuclease to recognize the spacer sequence in the type II CRISPR / Cas9 gene editing system of Example 1 of the present invention. The nucleotide sequences of HqCas9, DspCas9, and DsuCas9 are shown in SEQ ID NOs. 10 to 12, respectively.
[0037] The specific operations are as follows:
[0038] (1) Six random bases NNNNNN were added to the 3' end of the PAM library spacer sequence (whose sequence is shown in SEQ ID NO.14) (a total of 4096 inserts). The library was constructed into the pUC19 backbone vector using the overlap PCR method, resulting in a PAM library plasmid with 4096 different PAM combinations. However, the 5' end spacer sequence was the same as the spacer-PAM hybrid plasmid. The Gini value of the random base abundance at the six positions was less than 0.1 detected by second-generation sequencing, indicating that the random bases at the six positions were evenly distributed and the PAM library plasmid had an Amp resistance gene.
[0039] (2) Construction of the pET28a-Cas9 plasmid for prokaryotic expression: The three CRISPR / Cas9 gene editing systems described in the present invention, including Cas9 protein, sgRNA and tracrRNA, were inserted into the EcoR I and BamH I restriction sites of the pET28a vector (addgene, 108303), respectively. The Cas9 protein was codon-optimized for Escherichia coli and a TAA termination codon was added at the end; 5'-repeat sequence-spacer sequence (complementary to the PAM library spacer sequence)-repeat sequence-3' was added after the heterologous promoter J23119 promoter, i.e., sgRNA was followed by a T7 terminator; the identified tracrRNA (whose sequences are shown in SEQ ID NO. 14 to 16, respectively) was added after the heterologous promoter J23119 promoter. The three plasmids have a Kana resistance gene.
[0040] (3) The plasmid containing pET28a-Cas9 (or pET28a empty plasmid) and PAM library was co-transfected into DH5α (Quanshijin Biotechnology, CD201-01) competent cells through bacterial electroporation. After recovery at 37℃ for 1 hour, it was evenly spread on a solid culture dish with dual resistance to Amp (100μg / mL) and Kana (50μg / mL). After incubation at 37℃ for 18 hours, all monoclonal colonies were scraped into non-resistant culture medium and centrifuged to extract the mixed plasmid containing pET28a-Cas9 (or pET28a empty plasmid) and PAM library plasmid.
[0041] (4) On the mixed plasmid, suitable primer pairs (library-NGS-F and library-NGS-R) were designed at both ends of random bases to carry out PCR amplification and purification of the position containing the spacer sequence and PAM combination. Adapters were added to both ends of the product (using commercial Illumina sequencing adapter primers: Hieff NGS384 Dual Index Primer Kit for Next-generation sequencing was performed using Set 1 (Cat. No. 12613ES02) (I5 primer: TAAGATTA) (I7 primer: GAGATTCC). The PAM depletion threshold of the pET28a empty control group was used as a reference. The depletion of six random bases was analyzed using Weblogo 3. The PAM sequence recognized by each Cas9 protein was obtained through negative screening.
[0042] The results of PAM sequence analysis are shown in Figure 2 . HqCas9, DspCas9, and DsuCas9 can recognize PAM sequences of NGNGNC, NNNAA, and NNNAA, respectively.
[0043] The above sequence information is as follows:
[0044] The sequence of the library-NGS-F primer is:
[0045] The sequences of the library-NGS-R primers are:
[0046] Example 3: Prokaryotic interference experiment 1
[0047] This example verifies that the three type II CRISPR / Cas9 gene editing systems of Example 1 of the present invention have cutting ability in prokaryotes (i.e., whether they can recognize the PAM sequence obtained in Example 2) through prokaryotic interference experiments, and verifies the correctness of the PAM identified in Example 2 of the present invention.
[0048] The specific operations are as follows:
[0049] (1) Construct a PAM-target single plasmid and replace the 6 random bases of the PAM library plasmid constructed in Example 2 with the PAM sequences corresponding to the three Cas9 proteins (HqCas9: AGCGAC; DspCas9: GGATAA; DsuCas9: GGATAA).
[0050] (2) The PAM-target single plasmid was electroporated into the DH5α competent cells containing three Cas9 gene editing systems, and the PAM empty plasmid was used as a control. After 1 hour of recovery at 37°C, the culture medium was gradiently diluted. 20 μL of culture medium was drop-plated on a culture dish containing dual resistance to Amp (100 μg / mL) and Kana (50 μg / mL). After culturing at 37°C for 18 hours, the number of monoclonal bacteria on the dual resistance plate was observed.
[0051] The results of prokaryotic interference are shown in Figure 3. From right to left is the dilution direction, and the rightmost column is the undiluted original bacterial solution. The greater the dilution factor, the fewer monoclones grow. The control group is an electroporated PAM blank plasmid group. There is no target sequence that is complementary to the spacer sequence in the Cas9 gene editing system. The Cas9 protein cannot perform the cutting function, and the bacteria have double resistance genes and grow normally. The PAM single plasmid in the experimental group has a target site and PAM that can complement the spacer sequence in the Cas9 gene editing system. The number of monoclones in the experimental group decreased significantly compared with the control group, indicating that the Cas9 protein can recognize the PAM sequence selected in this example and exert its cutting ability, so that the bacteria do not have the ability to resist Amp and cannot grow. The experimental results show that the HqCas9, DspCas9, and DsuCas9 of the present invention can recognize PAM sequences with sequences of AGCGAC, GGATAA, and GGACAA, respectively, and have cutting ability in the prokaryotic system.
[0052] Example 4: Prokaryotic interference experiment 2
[0053] This example uses prokaryotic interference experiments to verify the tracrRNA range required for cutting the targeted DNA sequence in the three type II CRISPR / Cas9 gene editing systems of Example 1 of the present invention.
[0054] The specific operations are as follows:
[0055] (1) The noncoding regions (NC) in the three CRISPR / Cas9 gene editing systems of Example 1 of the present invention were divided into four segments, which were assembled into target plasmids by the Gibson method, and the strong heterologous promoter J23119 was added in front to construct target NC 1-4 plasmids respectively.
[0056] (2) Construction of pET28a-ΔCas9 plasmid: All NC parts were deleted from the pET28a-Cas9 plasmid obtained in Example 2, and the Cas9 protein, repeat sequence and spacer sequence were retained.
[0057] (3) The target NC 1-4 plasmids were electroporated into the competent Escherichia coli DH5α containing pET28a-ΔCas9. After 1 h of recovery at 37°C, the culture medium was diluted in a gradient manner. 20 μL of the culture medium was drop-plated on a culture dish containing dual resistance to Amp (100 μg / mL) and Kana (50 μg / mL). After incubation at 37°C for 18 h, the number of monoclonal bacteria on the dual resistance plate was observed.
[0058] The prokaryotic interference results are shown in Figure 4. The results show that the NC4 of HqCas9, NC2 of DspCas9, and NC1 of DsuCas9 correspond to the least growing colonies, indicating that the NC regions corresponding to these three segments are the main sequences that assist Cas9 nuclease in exerting an effective cutting effect.
[0059] Example 5: Predicting RNA secondary structures at target sites recognized by the CRISPR / Cas9 gene editing system
[0060] To predict the RNA secondary structure of the target site recognized by the three type II CRISPR / Cas9 gene editing systems in Example 1 of the present invention, the binding process between tracrRNA and the RNA transcribed from the repetitive sequence was simulated to predict the RNA secondary structure after the two were bound. The simulation was performed using the online software NUPACK. The results are shown in Figure 5. The repetitive sequence and tracrRNA are connected by "GAAA". The scaffold sequences required for the three CRISPR / Cas9 gene editing systems to achieve targeted cleavage are shown in SEQ ID NOs. 17 to 19.
[0061] The above sequence information is as follows:
[0062] Example 6: dsODN insertion experiment 1
[0063] This example uses dsODN insertion experiments to verify the optimal spacer sequence lengths for the three type II CRISPR / Cas9 gene editing systems of Example 1 of the present invention to achieve targeted cleavage in eukaryotic cells.
[0064] The specific operations are as follows:
[0065] (1) The three Cas9 proteins of Example 1 of the present invention were codon-optimized for human origin, and the corresponding nucleotide sequences were cloned into the PX330 eukaryotic expression vector (Addgene, 59909) to obtain the PX330-protein eukaryotic expression plasmid.
[0066] (2) In mammalian cells, taking HEK293T cells as an example, endogenous genes were selected and the PAM sequence identified in Example 3 that can be recognized and cleaved in prokaryotes was used to find a suitable target site. The sequence format was 5'-spacer sequence of different lengths (18-30 bp)-direct repeat sequence-3'. The sequence was cloned into the PXZ vector (Addgene, 160229) by the Gibson method. PXZ-target plasmids with different spacer lengths targeting the same target site were constructed. The PX330-protein eukaryotic expression plasmid and the PXZ-target plasmid were transfected simultaneously. The specific target sequences are shown in Table 1.
[0067] (3) HEK293T cells in good growth condition were co-transfected with PX330-protein eukaryotic plasmid, PXZ-target plasmid, and 1.2 μL dsODN in a 24-well plate. After 72 h, the cells were harvested and DNA was extracted.
[0068] (4) A pair of primers (see Table 1) were designed upstream of the corresponding gene target site and on the dsODN sequence for dsODN-PCR amplification. The agarose gel was run to detect whether the target band appeared to determine whether dsODN was inserted. By detecting the insertion of dsODN, it was verified whether the Cas9 gene editing system described in the present invention had editing ability in the eukaryotic cell environment, and the strength of the bands corresponding to the spacer sequences of different lengths were compared.
[0069] Table 1 Base size and sequence
[0070] The test results are shown in Figure 6. PCR bands of corresponding lengths are marked with red triangles, indicating dsODN insertion, demonstrating that all three CRISPR / Cas9 gene editing systems possess targeted cleavage capabilities in eukaryotic cells. Comparison of band intensities revealed that the optimal spacer recognition length for HqCas9 is 20-24 bp, for DspCas9 is 21-24 bp, and for DsuCas9 is 22-24 bp.
[0071] Example 7: dsODN insertion experiment 2
[0072] In this example, the on-target and off-target effects of the three type II CRISPR / Cas9 gene editing systems of Example 1 of the present invention were detected in eukaryotic cells through dsODN insertion experiments to detect the cutting effect.
[0073] The specific operations are as follows:
[0074] (a) Construction of site plasmid. The results of Example 6 have shown the optimal spacer lengths for the three Cas9s. In mammalian cells, taking HEK293T cells as an example, endogenous genes were selected to find suitable target sites (see Table 2). The sequence format was 5'-spacer sequence complementary to the target site-scaffold-3', and cloned into the PXZ vector by the Gibson method to construct the PXZ-target plasmid.
[0075] Table 2 Target sites and their sequences
[0076] (b) The PX330-protein eukaryotic expression plasmid prepared in Example 6, the PXZ-target plasmid, and 1.2 μL of dsODN were simultaneously electroporated. After 72 hours, the cells were harvested and DNA was extracted.
[0077] (c) Primers were designed upstream of the corresponding gene target site and on the dsODN sequence (see Table 1) for dsODN-PCR amplification. The appearance of the target band was detected on an agarose gel to determine whether dsODN was inserted. First, the insertion of dsODN was detected to verify whether the Cas9 gene editing system of the present invention had targeted cleavage at the selected target site.
[0078] (d) DNA with detectable dsODN-PCR bands was selected for GUIDE-seq library construction and next-generation sequencing was performed. Bioinformatics analysis was used to detect on-target and off-target cleavage of the three Cas9 gene editing systems.
[0079] The GUIDE-seq test results are shown in Figure 7. The three proteins have high on-target reads at the corresponding multiple target sites, and few off-target sites or no off-target sites can be detected, indicating that the HqCas9, DspCas9, and DsuCas9 gene editing systems described in the present invention all have strong cutting efficiency and good cutting specificity in eukaryotes.
[0080] In summary, the present invention identified three new type II CRISPR / Cas9 gene editing systems for the first time. The Cas9 proteins of the three new editing systems were named HqCas9, DspCas9, and DsuCas9, respectively. The above examples demonstrate that the three type II CRISPR / Cas9 gene editing systems of the present invention can recognize specific PAM sequences (NGNGNC, NNNAA, NNNAA) and can perform gene editing functions in prokaryotic environments or eukaryotic cells under the guidance of crRNA, greatly increasing the targetable range and overcoming the limitations of SpCas9.
[0081] The present invention selects prokaryotic and eukaryotic DNA to verify the editing ability of three type II CRISPR / Cas9 gene editing systems. The Cas9 protein needs a nucleotide sequence complementary to the crRNA spacer sequence and a recognizable PAM sequence to recognize the target sequence. First, the Cas9 protein of the present invention is proved to have cutting ability in prokaryotes by prokaryotic depletion experiments, and the PAM sequence recognized by the Cas9 protein in the prokaryotic system is known. The correctness of PAM is then verified by prokaryotic interference experiments and eukaryotic cell experiments. The present invention artificially designs the spacer sequence in crRNA, and the type II CRISPR / Cas9 gene editing system obtained can target almost all DNA sequences of interest in the genome, generating site-specific blunt-end double-strand breaks (DSBs). By repairing DSBs through non-homologous ends, small random insertions / deletions (indels) are generated at the cutting site to inactivate the target gene; or by high-fidelity homologous repair, a homologous repair template can be used to perform precise genome modification at the DSB site. The GUIDE-seq results show that the number of on-target edits of the two proteins is high, indicating high editing efficiency, and the small number of off-targets indicates high editing accuracy. HqCas9 recognizes the PAM sequence NGNGNC. This relatively complex PAM allows for more precise target site identification, improving the accuracy of Cas9 protein recognition. DspCas9 and DsuCas9 recognize similar PAMs, with both A's at positions 4 and 5. Both proteins can recognize target sites with the PAM NNNAA. Analysis of the frequency of "AA" sequence sites across the human genome revealed an average of one AA every 5 base pairs, significantly increasing the targeting range of DspCas9 and DsuCas9 across the human genome.
[0082] The discovery of the three type II CRISPR / Cas9 gene editing systems of the present invention further expands the types of gene editing tools, provides powerful research tools for scientific research and disease treatment, and plays an important role in promoting the application of gene editing in clinical treatment.
[0083] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solutions of the present invention.
Claims
1. A Cas9 protein, characterized in that The amino acid sequence of the Cas9 protein is shown in any one of SEQ ID NOs. 1 to 3.
2. A nucleotide sequence encoding the Cas9 protein according to claim 1, characterized in that: The nucleotide sequence is shown in any one of SEQ ID NOs. 10 to 12.
3. A type II CRISPR / Cas9 gene editing system, characterized in that: Comprising the Cas9 protein, auxiliary protein, CRISPR RNA and tracrRNA sequence as described in claim 1.
4. The type II CRISPR / Cas9 gene editing system according to claim 3, characterized in that The tracrRNA sequence includes a repetitive sequence, and the repetitive sequence is shown in any one of SEQ ID NOs. 7 to 9.
5. The type II CRISPR / Cas9 gene editing system according to claim 3 or 4, characterized in that The tracrRNA sequence is shown in any one of SEQ ID NOs. 14 to 16.
6. The type II CRISPR / Cas9 gene editing system according to claim 3, characterized in that The nucleotide sequence of the auxiliary protein is shown in any one of SEQ ID NOs. 4 to 6.
7. Use of the type II CRISPR / Cas9 gene editing system according to any one of claims 3 to 6 in gene editing in prokaryotes or eukaryotes.
8. Use of the type II CRISPR / Cas9 gene editing system according to any one of claims 3 to 6 in the preparation of biological gene editing preparations.
Citation Information
Patent Citations
Construction method of homologous type 2 CRISPR / Cas gene editing system
CN112331264A
Cpf1 protein and gene editing system
CN113234701A
Type 2 CRISPR / Cas9 gene editing system and application thereof
CN114075559A
Cas9 protein, type II CRISPR / Cas9 gene editing system and application
CN116751764A
Light emitting device, display apparartus including the same and manufacturing method of the same
KR1020240044983A
Cited By
SgRNA, CRISPR / FpCas9 gene editing system and application thereof
CN119709757A
Optimized Cas9 nucleic acid molecule and application thereof
CN121227754A
Methods for insertion and expression of a transgene in a genome
WO2026215134A1
